| |
Original Artikel |
Datum |
Titel |
Autoren Max. 6 Autoren |
| 1 |
[GO] |
2026―Jul―10 |
Virologic insights from the phase 3 REDPINE trial: remdesivir in renally impaired and immunocompromised patients with COVID-19 |
Lauren Rodriguez, Kristen Andreatta, Shuguang Chen, Yu Hu, Jiani Li, Ross Martin, Dong Han, Jasmine Moshiri, Jason K. Perry, Meghan E. Sise, Jose Ramon Santos, Markus Plate, Mark J. McPhail, Yiannis Koullias, Robert H. Hyland, Charlotte Hedskog, Zhaohui Qian |
| 2 |
[GO] |
2026―Jun―23 |
A community-based One Health approach to the pandemic dynamics of
Escherichia coli
ST131 |
Aiko Maeda, Toyotaka Sato, Akira Fukuda, Torahiko Okubo, Masaru Usui, Mana Tohyama, Jirachaya Toyting-Hiraishi, Naoyuki Tsukamoto, Akio Suzuki, Yuuji Hoshino, Shingo Torigoe, Keiichiro Sakakibara, Satoshi Tamai, Tooru Tachibana, Satoshi Takahashi, Shin-ichi Yokota, Motohiro Horiuchi, Alessandra Carattoli |
| 3 |
[GO] |
2026―Mai―11 |
Pharmacokinetic drug-drug interaction between the COVID-19 3CL protease inhibitor GST-HG171 and itraconazole in healthy subjects |
Xiaojiao Li, Bing Li, Meng Wang, Jing Wang, Jing Lu, John Mao, Tianxiang Zhang, Yanan Tang, Wenhao Yan, Chuanjing Li, George Zhang, Yanhua Ding, Zhaohui Qian |
| 4 |
[GO] |
2026―Apr―27 |
Synergistic antiviral effects of structure-guided peptides and a mutagenic base analog on SARS-CoV-2 replication |
Sergio Ortega Del Campo, Gregorio Joaquín Fernández Ballester, Clara Blanes Mira, Víctor Guirado Osorio, Luis Díaz Martínez, Ana Isabel de Ávila, María Eugenia Soria, Brenda Martínez-González, Francisco José Villena González, Josefa Gómez-Maldonado, María Isabel Viciana Ramos, Encarnación Clavijo Frutos, Jesús L. Santos González, Ugo Bastolla, Celia Perales, Esteban Domingo, Enrique Viguera, Ana María Fernández Escamilla, Ana Grande Pérez, Zhaohui Qian |
| 5 |
[GO] |
2026―Mrz―23 |
Multifunctional ACE2-nanobody fusion design for pan-specific neutralization and cardiovascular protection in SARS coronavirus infection |
Traian Sulea, Matthew Stuible, Maria Moreno, Alex Pelletier, Martin A. Rossotti, Yuneivy Cepero-Donates, Jacqueline Slinn, Patrick Salois, Anh Tran, Melissa Hewitt, Alvaro Yogi, Nazanin Rohani, Brian Cass, Anne E. G. Lenferink, Jamshid Tanha, Binbing Ling, Etienne Lessard, Laurence Delafosse, Jagdeep K. Sandhu, Danica Stanimirovic, Zhaohui Qian |
| 6 |
[GO] |
2026―Feb―09 |
Spatiotemporal dynamics and multiple driving factors of antimicrobial resistance in China during the COVID-19 pandemic (2019-2023): a provincial panel data analysis |
Xu Zheng, Xiaoyan You, Yu Liu, Binwei Wu, Boudewijn L. de Jonge |
| 7 |
[GO] |
2025―Sep―26 |
Immunocompromised patients with persistent SARS-CoV-2 viral shedding ≥8 weeks, clinical outcomes, and virological dynamics: a retrospective multicenter cohort study, 2020-2024 |
Clémentine de La Porte des Vaux, Nicolas Veyrenche, Kevin Da Silva, Nathalie Chavarot, Marianne Burgard, Olivier Paccoud, Florence Runyo, Margaux Garzaro, Claire Rouzaud, Alexandra Serris, Damien Vimpere, Dany Anglicheau, Luc Mouthon, Olivier Hermine, Marie-Anne Rameix-Welti, Fanny Lanternier, Olivier Lortholary, Cléa Melenotte, Miguel Angel Martinez |
| 8 |
[GO] |
2025―Jun―24 |
Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trial |
Matthew Tate, Christopher J. R. Illingworth, Gordon MacGregor, Laura Cunningham, Laura Divers, Elaine McCartney, Lucy Paterson, Caroline Kelly, Ann Shaw, Jonathan S. Perkins, Vanessa Silva, Poppy Holland, Carol Dalton, Samantha Carmichael, Elizabeth Douglas, Pamela Surtees, Janet T. Scott, Colin Berry, Sreenu Vattipally, Ana Da Silva Filipe, Lily Tong, Rory Gunson, Iain B. McInnes, Robert Jones, Emma Thomson, Kevin G. Blyth, Claire Rooney, Erin McGarry, Rosemary Meharry, Lauren Devers, Lisa Akyol, Jennifer Pearson, Sarah Nichol, Helen Casey, Michael McGettrick, James Brock, Nathan Smith, Rebecca McCall, Miguel Angel Martinez |
| 9 |
[GO] |
2025―Jun―23 |
Synthetic host defense peptide inhibits SARS-CoV-2 replication
in vitro |
Rhodri Harfoot, Blair Lawley, Leonor C. Hernández, Joanna Kuang, Francesca R. Hills, Shubhra Sinha, Margot J. M. Allais, Tom W. Bird, Cody P. Hird, John A. Taylor, Mihnea Bostina, Davide Comoletti, Evan F. Haney, Robert E. W. Hancock, Daniel Pletzer, Miguel E. Quiñones-Mateu, Miguel Angel Martinez |
| 10 |
[GO] |
2025―Mrz―10 |
Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrier |
Liwei Zhao, Chuang Li, Mengyu Wang, Minyun Zhou, Lei Jiang, Wanying Zhang, Jie Yu, Wei Wang, Kangping Zhou, Kai Pan, Hoi-Yan Lam, Ivan Fan-Ngai Hung, Kwok-Hung Chan, Lian Liu, Feng Wang, Xiaofeng Zhao, Yuxin Chen, Miguel Angel Martinez |
| 11 |
[GO] |
2025―Jan―31 |
Single- and multiple-dose pharmacokinetics and safety of the SARS-CoV-2 3CL protease inhibitor RAY1216: a phase 1 study in healthy participants |
Yue Hu, Haijun Li, Kun Wang, Dandan Wu, Hong Zhang, Yanhua Ding, Junyan Wu, Suiwen Ye, Yun Peng, Li Liu, Miguel Angel Martinez |
| 12 |
[GO] |
2024―Dez―19 |
SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participants |
Lauren Rodriguez, Hery W. Lee, Jiani Li, Ross Martin, Dong Han, Simin Xu, Jasmine Moshiri, Nadine Peinovich, Gregory Camus, Jason K. Perry, Robert H. Hyland, Danielle P. Porter, Mazin Abdelghany, Matthias Götte, Charlotte Hedskog, Jared A. Silverman |
| 13 |
[GO] |
2024―Dez―17 |
Efficient
in vitro
assay for evaluating drug efficacy and synergy against emerging SARS-CoV-2 strains |
Maximillian Woodall, Samuel Ellis, Shengyuan Zhang, Japhette Kembou-Ringert, Kerry-Anne Kite, Laura Buggiotti, Amy I. Jacobs, Akosua Adom Agyeman, Tereza Masonou, Machaela Palor, Timothy D. McHugh, Judith Breuer, Joseph F. Standing, Claire M. Smith, Jared A. Silverman |
| 14 |
[GO] |
2024―Nov―07 |
Evidence that remdesivir treatment reduces viral titers in patients with COVID-19 |
Simon Boyd, Shivani Singh, William H. K. Schilling, Nicholas J. White, Miguel Angel Martinez |
| 15 |
[GO] |
2024―Nov―07 |
Reply to Boyd et al., “Evidence that remdesivir treatment reduces viral titers in patients with COVID-19” |
Isa Faghihi, Victoria C. Yan, Miguel Angel Martinez |
| 16 |
[GO] |
2024―Okt―29 |
Intranasal liposomal angiotensin-(1-7) administration reduces inflammation and viral load in the lungs during SARS-CoV-2 infection in K18-hACE2 transgenic mice |
Sabrina Mendes, Lays Cordeiro Guimarães, Pedro Augusto Carvalho Costa, Clara Couto Fernandez, Maria Marta Figueiredo, Mauro Martins Teixeira, Robson Augusto Souza dos Santos, Pedro Pires Goulart Guimarães, Frédéric Frézard, Miguel Angel Martinez |
| 17 |
[GO] |
2024―Sep―06 |
Oral pharmacokinetics and efficacy of oral phospholipid remdesivir nucleoside prodrugs against SARS-CoV-2 in mice |
Aaron F. Carlin, James R. Beadle, Jeremy Ardanuy, Alex E. Clark, Victoria Rhodes, Aaron F. Garretson, Joyce A. Murphy, Nadejda Valiaeva, Robert T. Schooley, Matthew B. Frieman, Karl Y. Hostetler, Miguel Angel Martinez |
| 18 |
[GO] |
2024―Sep―03 |
Design of novel and highly selective SARS-CoV-2 main protease inhibitors |
Adi N. R. Poli, Ian Tietjen, Nitesh K. Nandwana, Joel Cassel, Troy E. Messick, Emery T. Register, Frederick Keeney, Rajesh Rajaiah, Atul K. Verma, Kabita Pandey, Arpan Acharya, Siddappa N. Byrareddy, Luis J. Montaner, Joseph M. Salvino, Miguel Angel Martinez |
| 19 |
[GO] |
2024―Aug―29 |
Efficacy of ensitrelvir for cough due to COVID-19 Omicron variant in medical healthcare workers |
Naoyuki Miyashita, Yasushi Nakamori, Makoto Ogata, Naoki Fukuda, Akihisa Yamura, Tomoki Ito, Miguel Angel Martinez |
| 20 |
[GO] |
2024―Aug―28 |
Identification of novel and potent inhibitors of SARS-CoV-2 main protease from DNA-encoded chemical libraries |
Dario Akaberi, Monireh Pourghasemi Lati, Janina Krambrich, Julia Berger, Grace Neilsen, Emilia Strandback, S. Pauliina Turunen, Johan Wannberg, Hjalmar Gullberg, Martin Moche, Praveen Kumar Chinthakindi, Tomas Nyman, Stefan G. Sarafianos, Anja Sandström, Josef D. Järhult, Kristian Sandberg, Åke Lundkvist, Oscar Verho, Johan Lennerstrand, Miguel Angel Martinez |
| 21 |
[GO] |
2024―Jul―18 |
Remdesivir treatment does not reduce viral titers in patients with COVID-19 |
Isa Faghihi, Victoria C. Yan, Miguel Angel Martinez |
| 22 |
[GO] |
2024―Jul―17 |
H
2
inhalation therapy in patients with moderate COVID-19 (H
2
COVID): a prospective ascending-dose phase I clinical trial |
C. Salomez-Ihl, J. Giai, M. Barbado, A. Paris, S. Touati, J. P. Alcaraz, S. Tanguy, C. Leroy, A. Lehmann, B. Degano, M. Gavard, P. Bedouch, P. Pavese, A. Moreau-Gaudry, M. Roustit, F. Boucher, P. Cinquin, J. P. Brion, Miguel Angel Martinez |
| 23 |
[GO] |
2024―Mai―14 |
Inhibition of endocytic uptake of severe acute respiratory syndrome coronavirus 2 and endo-lysosomal acidification by diphenoxylate |
Jin Soo Shin, Yejin Jang, Dong-Su Kim, Eunhye Jung, Myoung Kyu Lee, Byungil Kim, Sunjoo Ahn, Yeonju Shin, Su San Jang, Chang Soo Yun, Jongman Yoo, Young Chang Lim, Soo Bong Han, Meehyein Kim, Miguel Angel Martinez |
| 24 |
[GO] |
2024―Mrz―27 |
Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19 |
Lindsay E. Clegg, Oleg Stepanov, Henning Schmidt, Weifeng Tang, Huixia Zhang, Chris Webber, Taylor S. Cohen, Mark T. Esser, Mats Någård, Miguel Angel Martinez |
| 25 |
[GO] |
2024―Mrz―12 |
Two-way pharmacodynamic modeling of drug combinations and its application to pairs of repurposed Ebola and SARS-CoV-2 agents |
Shuang Xu, Shadisadat Esmaeili, E. Fabian Cardozo-Ojeda, Ashish Goyal, Judith M. White, Stephen J. Polyak, Joshua T. Schiffer, James E. Leggett |
| 26 |
[GO] |
2024―Mrz―06 |
BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir |
Wen-Fang Tang, Yu-Hsiu Chang, Cheng-Chin Lin, Jia-Rong Jheng, Chung-Fan Hsieh, Yuan-Fan Chin, Tein-Yao Chang, Jin-Ching Lee, Po-Huang Liang, Chia-Yi Lin, Guan-Hua Lin, Jie-Yun Cai, Yu-Li Chen, Yuan-Siao Chen, Shan-Ko Tsai, Ping-Cheng Liu, Chuen-Mi Yang, Tolou Shadbahr, Jing Tang, Yu-Lin Hsu, Chih-Heng Huang, Ling-Yu Wang, Cheng Cheung Chen, Jyh-Hwa Kau, Yi-Jen Hung, Hsin-Yi Lee, Wen-Chieh Wang, Hui-Ping Tsai, Jim-Tong Horng, Miguel Angel Martinez |
| 27 |
[GO] |
2024―Feb―06 |
Repurposing screen identifies novel candidates for broad-spectrum coronavirus antivirals and druggable host targets |
Sibylle Haid, Alina Matthaei, Melina Winkler, Svenja M. Sake, Antonia P. Gunesch, Vanessa Milke, Natalie M. Köhler, Jessica Rückert, Gabrielle Vieyres, David Kühl, Tu-Trinh Nguyen, Matthias Göhl, Lisa Lasswitz, Francisco J. Zapatero-Belinchón, Graham Brogden, Gisa Gerold, Bettina Wiegmann, Ursula Bilitewski, Richard J. P. Brown, Mark Brönstrup, Thomas F. Schulz, Thomas Pietschmann, Miguel Angel Martinez |
| 28 |
[GO] |
2024―Jan―31 |
Manidipine is not a potential inhibitor against SARS-CoV-2 main protease |
Rui Zhang, Jiahao Zhou, Haohao Yan, Xiaoping Liu, Chao Shang, Yunyu Chen, Miguel Angel Martinez |
| 29 |
[GO] |
2024―Jan―30 |
Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19 |
Hui Yang, Xin Yu, Wenjing Hou, Xiangduan Liu, Jiaojiao Chen, Ying Zhang, Ying Wang, Ying Zhu, Qing Qian, Kuifen Ma, Zhuoling An, James E. Leggett |
| 30 |
[GO] |
2023―Dez―15 |
Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171 |
Hong Zhang, Jing Zhou, Hong Chen, John Mao, Yanan Tang, Wenhao Yan, Tianxiang Zhang, Chuanjing Li, Shikui Chen, Guoping Li, George Zhang, Yanhua Ding, Li Liu, Miguel Angel Martinez |
| 31 |
[GO] |
2023―Dez―04 |
Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance |
Julie M. Strizki, John M. Gaspar, John A. Howe, Beth Hutchins, Hiroshi Mohri, Manoj S. Nair, Keith C. Kinek, Philip McKenna, Shih Lin Goh, Nicholas Murgolo, Miguel Angel Martinez |
| 32 |
[GO] |
2023―Okt―06 |
Evaluation of
in vitro
antiviral activity of SARS-CoV-2 M
pro
inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions |
Xiao Tong, Walter Keung, Lee D. Arnold, Laura J. Stevens, Andrea J. Pruijssers, Seunghyi Kook, Uri Lopatin, Mark Denison, Ann D. Kwong, Miguel Angel Martinez |
| 33 |
[GO] |
2023―Jun―06 |
Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab |
Rosalía Palomino-Cabrera, Francisco Tejerina, Andrea Molero-Salinas, María Ferris, Cristina Veintimilla, Pilar Catalán, Gabriela Rodríguez Macias, Roberto Alonso, Patricia Muñoz, Darío García de Viedma, Laura Pérez-Lago, Luis Alcalá, Teresa Aldámiz, Roberto Alonso, Ana Álvarez-Uría, Elena Bermúdez, Emilio Bouza, Sergio Buenestado-Serrano, Almudena Burillo, Raquel Carrillo, Pilar Catalán, Emilia Cercenado, Alejandro Cobos, Cristina Díez, Pilar Escribano, Agustín Estévez, Chiara Fanciulli, Alicia Galar, Ma Dolores García, Darío García de Viedma, Paloma Gijón, Helmuth Guillén, Jesús Guinea, Marta Herranz, Álvaro Irigoyen, Martha Kestler, Juan Carlos López, Marina Machado, Mercedes Marín, Pablo Martín-Rabadán, Andrea Molero-Salinas, Pedro Montilla, Patricia Muñoz, Belén Padilla, Rosalía Palomino-Cabrera, María Palomo, María Jesús Pérez-Granda, Daniel Peñas-Utrilla, Laura Pérez-Lago, Leire Pérez, Elena Reigadas, Cristina Rincón, Belén Rodríguez, Sara Rodríguez, Cristina Rodríguez-Grande, Adriana Rojas, María Jesús Ruiz-Serrano, Carlos Sánchez, Mar Sánchez, Amadeo Sanz-Pérez, Julia Serrano, Francisco Tejerina, Maricela Valerio, Ma Cristina Veintimilla, Lara Vesperinas, Teresa Vicente, Sofía de la Villa |
| 34 |
[GO] |
2023―Mrz―28 |
Inhibition of Human Coronaviruses by Combinations of Host-Targeted and Direct-Acting Antivirals |
Patricia de León, Rodrigo Cañas-Arranz, María José Bustos, Margarita Sáiz, Francisco Sobrino |
| 35 |
[GO] |
2023―Jan―05 |
Atypical Mutational Spectrum of SARS-CoV-2 Replicating in the Presence of Ribavirin |
Pilar Somovilla, Carlos García-Crespo, Brenda Martínez-González, María Eugenia Soria, Ana Isabel de Ávila, Isabel Gallego, Pablo Mínguez, Antoni Durán-Pastor, Cristina Ferrer-Orta, Llanos Salar-Vidal, Mario Esteban-Muñoz, Sonia Zuñiga, Isabel Sola, Luis Enjuanes, Jaime Esteban, Ricardo Fernandez-Roblas, Ignacio Gadea, Jordi Gómez, Nuria Verdaguer, Esteban Domingo, Celia Perales |
| 36 |
[GO] |
2022―Dez―15 |
Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19 |
Elizabeth E. Zumbrun, Chengzi I. Kaku, Lukas Dillinger, Samantha E. Zak, Ana I. Kuehne, Russel R. Bakken, Jeffrey W. Koehler, Korey L. Delp, Christopher P. Stefan, Raina Kumar, Jeffrey R. Kugelman, Alicia M. Moreau, Xiankun Zeng, John M. Dye, Andrew S. Herbert, Kristin Narayan, Laura M. Walker |
| 37 |
[GO] |
2022―Dez―14 |
A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19 |
Yeon-Sook Kim, Seng-Ho Jeon, Junghee Kim, Jong Hoon Koh, Seung Won Ra, Ji Won Kim, Yeonjae Kim, Choon Kwan Kim, Yun Chul Shin, Beo Deul Kang, Seung ji Kang, Chul Hee Park, Boyoung Lee, Ji Yeon Lee, Chung Hoon Lee, Jae-phil Choi, Jin Yong Kim, Shi Nae Yu, Kyong Ran Peck, Sung-Han Kim, Jung Yeon Heo, Hyun ah Kim, Hyun-jin Park, JoungWon Choi, Jumi Han, JooHyun Kim, Hyoung jun Kim, Se Hee Han, Aeri Yoon, MiHee Park, SuJung Park, YuKyung Kim, Minji Jung, Myoung-don Oh |
| 38 |
[GO] |
2022―Nov―14 |
Lancemaside A from Codonopsis lanceolata: Studies on Antiviral Activity and Mechanism of Action against SARS-CoV-2 and Its Variants of Concern |
Tai Young Kim, Sangeun Jeon, Meehyun Ko, Young Eun Du, So-Ri Son, Dae Sik Jang, Seungtaek Kim, C. Justin Lee |
| 39 |
[GO] |
2022―Okt―26 |
Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis |
Tilman Lingscheid, Martina Kinzig, Anne Krüger, Nils Müller, Georg Bölke, Pinkus Tober-Lau, Friederike Münn, Helene Kriedemann, Martin Witzenrath, Leif E. Sander, Fritz Sörgel, Florian Kurth |
| 40 |
[GO] |
2022―Sep―13 |
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part |
Hiroshi Mukae, Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Takumi Imamura, Takuhiro Sonoyama, Takahiro Fukuhara, Genki Ichihashi, Takao Sanaki, Keiko Baba, Yosuke Takeda, Yuko Tsuge, Takeki Uehara |
| 41 |
[GO] |
2022―Sep―12 |
Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults |
Ryosuke Shimizu, Takuhiro Sonoyama, Takahiro Fukuhara, Aya Kuwata, Yumiko Matsuo, Ryuji Kubota |
| 42 |
[GO] |
2022―Jul―12 |
New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19 |
Robert L. Atmar, Natalie Finch |
| 43 |
[GO] |
2022―Jul―05 |
Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces |
Delphine Lapaillerie, Cathy Charlier, Véronique Guyonnet-Dupérat, Emilie Murigneux, Henrique S. Fernandes, Fábio G. Martins, Rita P. Magalhães, Tatiana F. Vieira, Clémence Richetta, Frédéric Subra, Samuel Lebourgeois, Charlotte Charpentier, Diane Descamps, Benoît Visseaux, Pierre Weigel, Alexandre Favereaux, Claire Beauvineau, Frédéric Buron, Marie-Paule Teulade-Fichou, Sylvain Routier, Sarah Gallois-Montbrun, Laurent Meertens, Olivier Delelis, Sérgio F. Sousa, Vincent Parissi |
| 44 |
[GO] |
2022―Jun―23 |
Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric Studies |
James A. Watson, Stephen M. Kissler, Nicholas P. J. Day, Yonatan H. Grad, Nicholas J. White |
| 45 |
[GO] |
2022―Jun―16 |
In Vitro
Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance |
Liva Checkmahomed, Julie Carbonneau, Venice Du Pont, Nicholas C. Riola, Jason K. Perry, Jiani Li, Bastien Paré, Shawn M. Simpson, Martin A. Smith, Danielle P. Porter, Guy Boivin |
| 46 |
[GO] |
2022―Jun―15 |
Dual Inhibition of Vacuolar-ATPase and TMPRSS2 Is Required for Complete Blockade of SARS-CoV-2 Entry into Cells |
Simoun Icho, Edurne Rujas, Krithika Muthuraman, John Tam, Huazhu Liang, Shelby Landreth, Mingmin Liao, Darryl Falzarano, Jean-Philippe Julien, Roman A. Melnyk |
| 47 |
[GO] |
2022―Jun―01 |
Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients |
E. Leegwater, D. J. A. R. Moes, L. B. E. Bosma, T. H. Ottens, I. M. van der Meer, C. van Nieuwkoop, E. B. Wilms |
| 48 |
[GO] |
2022―Mai―09 |
Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants |
Jared Pitts, Jiani Li, Jason K. Perry, Venice Du Pont, Nicholas Riola, Lauren Rodriguez, Xianghan Lu, Chaitanya Kurhade, Xuping Xie, Gregory Camus, Savrina Manhas, Ross Martin, Pei-Yong Shi, Tomas Cihlar, Danielle P. Porter, Hongmei Mo, Evguenia Maiorova, John P. Bilello |
| 49 |
[GO] |
2022―Feb―22 |
Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: A Phase 2/3, Multicenter, Randomized, Open-label, Controlled Trial |
Run Dong, Li Jiang, Ting Yang, Changsong Wang, Yi Zhang, Xu Chen, Jianfeng Xie, Yuanbin Guo, Li Weng, Yan Kang, Kaijiang Yu, Haibo Qiu, Bin Du |
| 50 |
[GO] |
2022―Feb―22 |
Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial |
Run Dong, Li Jiang, Ting Yang, Changsong Wang, Yi Zhang, Xu Chen, Jianfeng Xie, Yuanbin Guo, Li Weng, Yan Kang, Kaijiang Yu, Haibo Qiu, Bin Du |
| 51 |
[GO] |
2022―Jan―03 |
Reply to Casalini et al., “Bacterial Coinfections in COVID-19 Patients without a Positive Microbiologic Result: a Word of Caution” |
Jonathan Baghdadi, Sarah Bejo, Anthony Harris |
| 52 |
[GO] |
2022―Jan―03 |
Bacterial Coinfections in COVID-19 Patients without a Positive Microbiologic Result: a Word of Caution |
Giacomo Casalini, Giacomo Pozza, Andrea Giacomelli, Spinello Antinori |
| 53 |
[GO] |
2021―Dez―13 |
Early Use of Sarilumab in Patients Hospitalised with COVID-19 Pneumonia and Features of Systemic Inflammation. |
Nicolás Merchante, Sheila Cárcel, José Carlos Garrido-Gracia, Marta Trigo-Rodríguez, María Ángeles Esteban Moreno, Rafael León-López, Reinaldo Espíndola-Gómez, Eduardo Aguilar Alonso, David Vinuesa García, Alberto Romero-Palacios, Inés Pérez-Camacho, Belén Gutiérrez-Gutiérrez, Francisco Javier Martínez-Marcos, Concepción Fernández-Roldán, Pedro María Martínez Pérez-Crespo, Alexandra Aceituno Caño, Eva León, Juan E. Corzo, Carmen de la Fuente, Julián Torre-Cisneros |
| 54 |
[GO] |
2021―Dez―13 |
Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial |
Nicolás Merchante, Sheila Cárcel, José Carlos Garrido-Gracia, Marta Trigo-Rodríguez, María Ángeles Esteban Moreno, Rafael León-López, Reinaldo Espíndola-Gómez, Eduardo Aguilar Alonso, David Vinuesa García, Alberto Romero-Palacios, Inés Pérez-Camacho, Belén Gutiérrez-Gutiérrez, Francisco Javier Martínez-Marcos, Concepción Fernández-Roldán, Pedro María Martínez Pérez-Crespo, Alexandra Aceituno Caño, Eva León, Juan E. Corzo, Carmen de la Fuente, Julián Torre-Cisneros |
| 55 |
[GO] |
2021―Nov―22 |
A photoactivable natural product with broad antiviral activity against enveloped viruses including highly pathogenic coronaviruses |
Thomas Meunier, Lowiese Desmarets, Simon Bordage, Moussa Bamba, Kévin Hervouet, Yves Rouillé, Nathan François, Marion Decossas, Valentin Sencio, François Trottein, Fézan Honora Tra Bi, Olivier Lambert, Jean Dubuisson, Sandrine Belouzard, Sevser Sahpaz, Karin Séron |
| 56 |
[GO] |
2021―Okt―11 |
MOXIDECTIN AND IVERMECTIN INHIBIT SARS-COV-2 REPLICATION IN VERO E6 CELLS BUT NOT IN HUMAN PRIMARY AIRWAY EPITHELIUM CELLS |
Nilima Dinesh Kumar, Bram M. ter Ellen, Ellen M. Bouma, Berit Troost, Denise P. I. van de Pol, Heidi H. van der Ende-Metselaar, Djoke van Gosliga, Leonie Apperloo, Orestes A. Carpaij, Maarten van den Berge, Martijn C. Nawijn, Ymkje Stienstra, Izabela A Rodenhuis-Zybert, Jolanda M. Smit |
| 57 |
[GO] |
2021―Sep―20 |
The natural stilbenoid (-)-hopeaphenol inhibits cellular entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7 and B.1.351 variants |
Ian Tietjen, Joel Cassel, Emery T. Register, Xiang Yang Zhou, Troy E. Messick, Frederick Keeney, Lily D. Lu, Karren D. Beattie, Topul Rali, Pablo Tebas, Hildegund C. J. Ertl, Joseph M. Salvino, Rohan A. Davis, Luis J. Montaner |
| 58 |
[GO] |
2021―Sep―07 |
Antibiotic Use and Bacterial Infection Among Inpatients in the First Wave of COVID-19: A Retrospective Cohort Study of 64,691 Patients |
Jonathan D. Baghdadi, KC Coffey, Timileyin Adediran, Katherine E. Goodman, Lisa Pineles, Larry S. Magder, Lyndsay M. O’Hara, Beth L. Pineles, Gita Nadimpalli, Daniel J. Morgan, Anthony D. Harris |
| 59 |
[GO] |
2021―Sep―07 |
Safety, tolerability, pharmacokinetics and immunogenicity of a monoclonal antibody (SCTA01) targeting SARS-CoV-2 in healthy adults: A randomized, double-blind, placebo-controlled, phase I study |
Yinjuan Li, Lu Qi, Haihong Bai, Chunyun Sun, Shuping Xu, Yu Wang, Chunyu Han, Yan Li, Long Liu, Xiaoqiang Cheng, Ju Liu, Chunpu Lei, Yuanxu Tong, Mingli Sun, Lixin Yan, Weiqiu Chen, Xisheng Liu, Qing Liu, Liangzhi Xie, Xinghe Wang |
| 60 |
[GO] |
2021―Aug―02 |
Candida auris
Invasive Infections During a COVID-19 Case Surge |
Blake M. Hanson, An Q. Dinh, Truc T. Tran, Sebastian Arenas, Darryl Pronty, Hayley B. Gershengorn, Tanira Ferreira, Cesar A. Arias, Bhavarth S. Shukla |
| 61 |
[GO] |
2021―Jul―12 |
Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola |
Victoria C. Yan, Florian L. Muller |
| 62 |
[GO] |
2021―Jun―28 |
Pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal anti-SARS-CoV-2 antibody, for COVID-19-related moderate pneumonia: a randomized, double-blind, placebo-controlled, phase IIa study |
Benjamin Gaborit, Eric Dailly, Bernard Vanhove, Régis Josien, Karine Lacombe, Vincent Dubee, Virginie Ferre, Sophie Brouard, Florence Ader, Marie-Anne Vibet, Aurélie Le Thuaut, Richard Danger, Laurent Flet, Anne Omnes, Laetitia Berly, Anne Chiffoleau, Alexandra Jobert, Odile Duvaux, François Raffi |
| 63 |
[GO] |
2021―Jun―17 |
Erratum for Lu et al., “Development of a Simple
In Vitro
Assay To Identify and Evaluate Nucleotide Analogs against SARS-CoV-2 RNA-Dependent RNA Polymerase” |
Gaofei Lu, Xi Zhang, Weinan Zheng, Jialei Sun, Lan Hua, Lan Xu, Xin-jie Chu, Sheng Ding, Wen Xiong |
| 64 |
[GO] |
2021―Jun―13 |
Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2
in Vitro |
Karen A. Gammeltoft, Yuyong Zhou, Carlos R. Duarte Hernandez, Andrea Galli, Anna Offersgaard, Rui Costa, Long V. Pham, Ulrik Fahnøe, Shan Feng, Troels K. H. Scheel, Santseharay Ramirez, Jens Bukh, Judith M. Gottwein |
| 65 |
[GO] |
2021―Mai―17 |
Nodosome inhibition as a novel broad-spectrum antiviral strategy against arboviruses, enteroviruses and SARS-CoV-2 |
Daniel Limonta, Lovely Dyna-Dagman, William Branton, Valeria Mancinelli, Tadashi Makio, Richard W. Wozniak, Christopher Power, Tom C. Hobman |
| 66 |
[GO] |
2021―Mai―11 |
Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab in Chinese Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Phase 1 Study |
Xiaojie Wu, Nanyang Li, Guoqin Wang, Wei Liu, Jicheng Yu, Guoying Cao, Jingjing Wang, Yuancheng Chen, Juan Ma, Jufang Wu, Haijing Yang, Xiaomeng Mao, Jinjie He, Yiqi Yu, Chao Qiu, Ning Li, Sheng Yao, Hui Feng, Jinghua Yan, Wenhong Zhang, Jing Zhang |
| 67 |
[GO] |
2021―Apr―28 |
Luminore CopperTouch™ surface coating effectively inactivates SARS-CoV-2, Ebola and Marburg in vitro |
Emily K. Mantlo, Slobodan Paessler, Alexey Seregin, Alfred Mitchell |
| 68 |
[GO] |
2021―Apr―28 |
Overcoming culture restriction for SARS-CoV-2 in human cells facilitates the screening of compounds inhibiting viral replication |
Santseharay Ramirez, Carlota Fernandez-Antunez, Andrea Galli, Alexander Underwood, Long V. Pham, Line A. Ryberg, Shan Feng, Martin S. Pedersen, Lotte S. Mikkelsen, Sandrine Belouzard, Jean Dubuisson, Christina Sølund, Nina Weis, Judith M. Gottwein, Ulrik Fahnøe, Jens Bukh |
| 69 |
[GO] |
2021―Mrz―03 |
Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2 |
Wendy P. Painter, Wayne Holman, Jim A. Bush, Firas Almazedi, Hamzah Malik, Nicola C. J. E. Eraut, Merribeth J. Morin, Laura J. Szewczyk, George R. Painter |
| 70 |
[GO] |
2021―Mrz―03 |
The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells |
Yuriko Tomita, Makoto Takeda, Shutoku Matsuyama |
| 71 |
[GO] |
2021―Feb―09 |
Considering personalized Interferon-β therapy for COVID-19 |
Karim Dorgham, Avidan U. Neumann, Maxens Decavele, Charles-Edouard Luyt, Hans Yssel, Guy Gorochov |
| 72 |
[GO] |
2021―Feb―09 |
Plitidepsin: a repurposed drug for the treatment of COVID-19 |
Miguel Angel Martinez |
| 73 |
[GO] |
2021―Feb―09 |
AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19 |
Steven S. Good, Jonna Westover, Kie Hoon Jung, Xiao-Jian Zhou, Adel Moussa, Paolo La Colla, Gabriella Collu, Bruno Canard, Jean-Pierre Sommadossi |
| 74 |
[GO] |
2021―Feb―09 |
Reply to letter “Considering personalized Interferon-β therapy for COVID-19” |
Effat Davoudi-Monfared, Hossein Khalili |
| 75 |
[GO] |
2021―Feb―09 |
Remdesivir for COVID-19: Why Not Dose Higher? |
Victoria C. Yan, Florian L. Muller |
| 76 |
[GO] |
2021―Jan―29 |
Kinetic characterization and inhibitor screening for the proteases leading to identification of drugs against SARS-CoV-2 |
Chih-Jung Kuo, Tai-Ling Chao, Han-Chieh Kao, Ya-Min Tsai, Yi-Kai Liu, Lily Hui-Ching Wang, Ming-Chang Hsieh, Sui-Yuan Chang, Po-Huang Liang |
| 77 |
[GO] |
2021―Jan―27 |
Limited Utility of Procalcitonin in Identifying Community-Associated Bacterial Infections in Patients Presenting with Coronavirus Disease 2019 |
Michael May, Michelle Chang, Donald Dietz, Sherif Shoucri, Justin Laracy, Magdalena E. Sobieszczyk, Anne-Catrin Uhlemann, Jason Zucker, Christine J. Kubin |
| 78 |
[GO] |
2020―Dez―08 |
Favipiravir and the Need for Early Ambulatory Treatment of COVID-19 |
Tony M. Korman |
| 79 |
[GO] |
2020―Dez―08 |
Evidence-Based Guidelines Should Be Used to Inform COVID-19 Management |
Thomas L. Holland |
| 80 |
[GO] |
2020―Nov―03 |
New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19 |
Muneerah M. Aleissa, Emily A. Silverman, Luisa M. Paredes Acosta, Cameron T. Nutt, Aaron G. Richterman, Francisco M. Marty |
| 81 |
[GO] |
2020―Okt―30 |
Repurposing Nucleoside Analogs for Human Coronaviruses |
Keivan Zandi, Franck Amblard, Katie Musall, Jessica Downs-Bowen, Ruby Kleinbard, Adrian Oo, Dongdong Cao, Bo Liang, Olivia O. Russell, Tamara McBrayer, Leda Bassit, Baek Kim, Raymond F. Schinazi |
| 82 |
[GO] |
2020―Okt―29 |
Development of a simple in vitro assay to identify and evaluate nucleotide analogs against SARS-CoV-2 RNA-dependent RNA polymerase |
Gaofei Lu, Xi Zhang, Weinan Zheng, Jialei Sun, Lan Hua, Lan Xu, Xin-jie Chu, Sheng Ding, Wen Xiong |
| 83 |
[GO] |
2020―Sep―23 |
Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV2 Infection (COVID-19) |
Peter A. McCullough |
| 84 |
[GO] |
2020―Sep―22 |
A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19 |
Yohei Doi, Masaya Hibino, Ryota Hase, Michiko Yamamoto, Yu Kasamatsu, Masahiro Hirose, Yoshikazu Mutoh, Yoshito Homma, Masaki Terada, Taku Ogawa, Fumihiro Kashizaki, Toshihiko Yokoyama, Hayato Koba, Hideki Kasahara, Kazuhisa Yokota, Hideaki Kato, Junichi Yoshida, Toshiyuki Kita, Yasuyuki Kato, Tadashi Kamio, Nobuhiro Kodama, Yujiro Uchida, Nobuhiro Ikeda, Masahiro Shinoda, Atsushi Nakagawa, Hiroki Nakatsumi, Tomoya Horiguchi, Mitsunaga Iwata, Akifumi Matsuyama, Sumi Banno, Takenao Koseki, Mayumi Teramachi, Masami Miyata, Shigeru Tajima, Takahiro Maeki, Eri Nakayama, Satoshi Taniguchi, Chang Kweng Lim, Masayuki Saijo, Takumi Imai, Hisako Yoshida, Daijiro Kabata, Ayumi Shintani, Yukio Yuzawa, Masashi Kondo |
| 85 |
[GO] |
2020―Sep―01 |
Removal of remdesivir's metabolite GS-441524 by hemodialysis in a double lung transplant recipient with COVID-19 |
Minh Patrick Lê, Quentin Le Hingrat, Pierre Jaquet, Paul-Henri Wicky, Vincent Bunel, Laurent Massias, Benoit Visseaux, Jonathan Messika, Diane Descamps, Hervé Mal, Jean-François Timsit, Gilles Peytavin |
| 86 |
[GO] |
2020―Aug―20 |
Antibiotic consumption and stewardship at a hospital outside of an early Coronavirus disease 2019 epicentre |
Deanna J. Buehrle, Brooke K. Decker, Marilyn M. Wagener, Amesh Adalja, Nina Singh, Mary C. McEllistrem, M. Hong Nguyen, Cornelius J. Clancy |
| 87 |
[GO] |
2020―Aug―06 |
Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production |
Natalia Fintelman-Rodrigues, Carolina Q. Sacramento, Carlyle Ribeiro Lima, Franklin Souza da Silva, André C. Ferreira, Mayara Mattos, Caroline S. de Freitas, Vinicius Cardoso Soares, Suelen da Silva Gomes Dias, Jairo R. Temerozo, Milene D. Miranda, Aline R. Matos, Fernando A. Bozza, Nicolas Carels, Carlos Roberto Alves, Marilda M. Siqueira, Patrícia T. Bozza, Thiago Moreno L. Souza |
| 88 |
[GO] |
2020―Jul―16 |
Discovery of M Protease inhibitors encoded by SARS-CoV-2 |
Hui-Chen Hung, Yi-Yu Ke, Sheng Yu Huang, Peng-Nien Huang, Yu-An Kung, Teng-Yuan Chang, Kuei-Jung Yen, Tzu-Ting Peng, Shao-En Chang, Chin-Ting Huang, Ya-Ru Tsai, Szu-Huei Wu, Shiow-Ju Lee, Jiunn-Horng Lin, Bing-Sin Liu, Wang-Chou Sung, Shin-Ru Shih, Chiung-Tong Chen, John Tsu-An Hsu |
| 89 |
[GO] |
2020―Jul―14 |
Efficacy and safety of interferon β-1a in treatment of severe COVID-19: A randomized clinical trial |
Effat Davoudi-Monfared, Hamid Rahmani, Hossein Khalili, Mahboubeh Hajiabdolbaghi, Mohamadreza Salehi, Ladan Abbasian, Hossein Kazemzadeh, Mir Saeed Yekaninejad |
| 90 |
[GO] |
2020―Jul―09 |
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations |
Catia Marzolini, Felix Stader, Marcel Stoeckle, Fabian Franzeck, Adrian Egli, Stefano Bassetti, Alexa Hollinger, Michael Osthoff, Maja Weisser, Caroline E. Gebhard, Veronika Baettig, Julia Geenen, Nina Khanna, Sarah Tschudin-Sutter, Daniel Mueller, Hans H. Hirsch, Manuel Battegay, Parham Sendi |
| 91 |
[GO] |
2020―Jul―03 |
Clinical trials of repurposed antivirals for SARS-CoV-2 |
Miguel Angel Martinez |
| 92 |
[GO] |
2020―Jun―23 |
IMPACT OF GLUCOCORTICOID TREATMENT IN SARS-COV-2 INFECTION MORTALITY: A RETROSPECTIVE CONTROLLED COHORT STUDY |
Ana Fernández Cruz, Belén Ruiz-Antorán, Ana Muñoz Gómez, Aránzazu Sancho López, Patricia Mills Sánchez, Gustavo Adolfo Centeno Soto, Silvia Blanco Alonso, Laura Javaloyes Garachana, Amy Galán Gómez, Ángela Valencia Alijo, Javier Gómez Irusta, Concepción Payares-Herrera, Ignacio Morrás Torre, Enrique Sánchez Chica, Laura Delgado Téllez de Cepeda, Alejandro Callejas Díaz, Antonio Ramos Martínez, Elena Múñez Rubio, Cristina Avendaño-Solá |
| 93 |
[GO] |
2020―Jun―08 |
The good, the bad & the hoax: when publication instantaneously impacts treatment strategies for COVID-19 |
François Danion, Yvon Ruch, Marion Fourtage, Charlotte Kaeuffer, Valentin Greigert, Nicolas Lefebvre, Joris Muller, Thierry Nai, Yves Hansmann |
| 94 |
[GO] |
2020―Jun―08 |
Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle |
Clarisse Salgado Benvindo da Silva, Melissa Thaler, Ali Tas, Natacha S. Ogando, Peter J. Bredenbeek, Dennis K. Ninaber, Ying Wang, Pieter S. Hiemstra, Eric J. Snijder, Martijn J. van Hemert |
| 95 |
[GO] |
2020―Mai―14 |
Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste |
James T. Gordy, Kaushiki Mazumdar, Noton K. Dutta |
| 96 |
[GO] |
2020―Mai―06 |
Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor Alisporivir (Debio 025) |
Laurent Softic, Rozenn Brillet, François Berry, Nazim Ahnou, Quentin Nevers, Margot Morin-Dewaele, Sabah Hamadat, Patrice Bruscella, Slim Fourati, Jean-Michel Pawlotsky, Abdelhakim Ahmed-Belkacem |
| 97 |
[GO] |
2020―Mai―05 |
Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs |
Sangeun Jeon, Meehyun Ko, Jihye Lee, Inhee Choi, Soo Young Byun, Soonju Park, David Shum, Seungtaek Kim |
| 98 |
[GO] |
2020―Apr―21 |
Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19 |
Markus Hoffmann, Simon Schroeder, Hannah Kleine-Weber, Marcel A. Müller, Christian Drosten, Stefan Pöhlmann |
| 99 |
[GO] |
2020―Mrz―19 |
Updated approaches against SARS-CoV-2 |
Haiou Li, Yunjiao Zhou, Meng Zhang, Haizhou Wang, Qiu Zhao, Jing Liu |
| 100 |
[GO] |
2020―Mrz―06 |
Compounds with therapeutic potential against novel respiratory 2019 coronavirus |
Miguel Angel Martinez |
|
